Aberdeen Group
DYN icon

Aberdeen Group’s Dyne Therapeutics DYN Stock Holding History

Aberdeen Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.2M Buy
1,539,434
+109,050
+8% +$2.03M 0.05% 305
2026
Q1 		$25.9M Buy
1,430,384
+322,239
+29% +$5.56M 0.04% 342
2025
Q4 		$21.7M Buy
1,108,145
+551,412
+99% +$10.4M 0.03% 399
2025
Q3 		$7.04M Buy
556,733
+72,770
+15% +$830K 0.01% 662
2025
Q2 		$4.61M Buy
483,963
+169,377
+54% +$1.86M 0.01% 712
2025
Q1 		$3.29M Buy
314,586
+288,783
+1,119% +$4.13M 0.01% 717
2024
Q4 		$608K Buy
+25,803
New +$763K ﹤0.01% 861
2024
Q3 		– Sell
-17,869
Closed -$631K – 930
2024
Q2 		$631K Buy
+17,869
New +$519K ﹤0.01% 847

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Aberdeen Group's DYN Position: Q2 2026 in Review

Aberdeen Group increased its Dyne Therapeutics (DYN) stake by 7.6% in Q2 2026, buying an estimated $2.03M and bringing the position to 1,539,434 shares worth $34.2M. The position accounts for 0.05% of the portfolio, ranked #305.

Aberdeen Group first reported a position in DYN in Q2 2024 and has held it in 8 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Aberdeen Group held 1,539,434 shares of Dyne Therapeutics worth $34.2M as of Q2 2026.
  • Aberdeen Group bought 109,050 Dyne Therapeutics shares in Q2 2026, an estimated $2.03M.
  • Dyne Therapeutics made up 0.05% of Aberdeen Group's portfolio in Q2 2026, its #305 holding.
  • Aberdeen Group first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.